Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Novel Triplet Shows Early Promise for Pretreated CLL

December 8th 2019

The triplet of umbralisib, ublituximab, and venetoclax induced a complete remission rate of 44% as a treatment for patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Tam on Results of the CAPTIVATE Trial in CLL

December 8th 2019

Constantine S. Tam, MD, MBBS, associate professor, Peter MacCallum Cancer Centre, discusses the results of the phase II CAPTIVATE study in chronic lymphocytic leukemia (CLL).

Acalabrutinib Triplet Highly Active in Frontline CLL

December 8th 2019

The triplet of acalabrutinib (Calquence), venetoclax (Venclexta), and obinutuzumab (Gazyva; AVO) is highly active as frontline therapy for patients with chronic lymphocytic leukemia.

Ibrutinib/Rituximab Combo Retains PFS Advantage Over FCR in CLL

December 8th 2019

With extended follow-up, progression-free survival continues to be superior with the combination of ibrutinib and rituximab compared with fludarabine, cyclophosphamide, and rituximab for patients ≤70 years with previously untreated chronic lymphocytic leukemia.

Frontline Ibrutinib/Venetoclax Combo Leads to High Rates of Undetectable MRD in CLL

December 8th 2019

The first-line combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) led to a 75% undetectable minimal residual disease rate in peripheral blood and 72% in bone marrow in patients with chronic lymphocytic leukemia.

Acalabrutinib Alone or in Combination Improves PFS in Frontline CLL

December 7th 2019

Acalabrutinib (Calquence) as a single agent or in combination with obinutuzumab (Gazyva) significantly improved progression-free survival compared with obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia.

Dr. Wierda on Chemoimmunotherapy in CLL

December 6th 2019

William G. Wierda, MD, PhD, discusses the use of chemoimmunotherapy in treating patients with chronic lymphocytic leukemia.

New BTK Agents and Combinations Are on the Horizon for B-cell Malignancies

December 5th 2019

During a recent OncLive Peer Exchange, a panel of leukemia and lymphoma experts discussed emerging BTK inhibitors.

Chemoimmunotherapy Role in CLL Shifting With Rise of Novel Agents

December 4th 2019

Jonathon B. Cohen, MD, MS, discusses the integration of novel agents into clinical practice and the changing role of chemoimmunotherapy in chronic lymphocytic leukemia.

Dr. Cohen on the ELEVATE-TN Trial in CLL

December 3rd 2019

Jonathon B. Cohen, MD, MS, associate professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, co-director, Lymphoma Program, and medical director, Infusion Services, Winship Cancer Institute of Emory University, discusses the design of the phase III ELEVATE-TN trial in chronic lymphocytic leukemia (CLL).

Dr. Mato on Ibrutinib Versus Acalabrutinib in CLL

November 23rd 2019

Anthony R. Mato, MD, MSCE, discusses differences between the use of ibrutinib (Imbruvica) and acalabrutinib (Calquence) in chronic lymphocytic leukemia (CLL).

Dr. Furman on Frontline Treatment Selection in CLL

November 22nd 2019

Richard R. Furman, MD, discusses the use of BTK inhibitors in chronic lymphocytic leukemia.

FDA Approves Acalabrutinib for CLL

November 21st 2019

The FDA has approved acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr. Mato on Ibrutinib-Based Combinations in CLL

November 21st 2019

Anthony R. Mato, MD, MSCE, discusses ibrutinib-based combinations in chronic lymphocytic leukemia.

Dr. Cohen on Fixed-Duration Therapy in CLL

November 21st 2019

Jonathon B. Cohen, MD, MS, discusses fixed-duration therapy in chronic lymphocytic leukemia.

Dr. Cohen on the Use of Chemoimmunotherapy in CLL

November 16th 2019

Jonathon B. Cohen, MD, MS, discusses the role of chemoimmunotherapy in chronic lymphocytic leukemia.

FDA Approval Sought for Ibrutinib/Rituximab in Frontline CLL/SLL

November 8th 2019

A supplemental new drug application has been submitted to the FDA for ibrutinib (Imbruvica) for use in combination with rituximab (Rituxan) for the first-line treatment of patients ≤70 years old with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr. Al-Sawaf on Testing for CKT in CLL

November 8th 2019

Othman Al-Sawaf, MD, discusses checking complex karyotype in patients with chronic lymphocytic leukemia.

Dr. Furman on Prognostic Markers in High-Risk CLL

November 7th 2019

Richard R. Furman, MD, discusses the role of prognostic markers in high-risk chronic lymphocytic leukemia.

Taking CLL Therapies From Bedside to Community

November 3rd 2019

Michael J. Keating, MBBS, has devoted much of his career to finding means of controlling chronic lymphocytic leukemia.